Hubbry Logo
Ralph S. BaricRalph S. BaricMain
Open search
Ralph S. Baric
Community hub
Ralph S. Baric
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Ralph S. Baric
Ralph S. Baric
Ralph S. Baric
View on Wikipedia
from Wikipedia

Ralph Steven Baric (born 1954) is an American epidemiologist. He is the William R. Kenan Jr. Distinguished Professor in the Department of Epidemiology, and professor in the Department of Microbiology and Immunology at the University of North Carolina at Chapel Hill.

Key Information

Baric's work involves coronaviruses, including gain of function research aimed at devising effective vaccines against coronaviruses.[1] Baric has warned of emerging coronaviruses presenting as a significant threat to global health, due to zoonosis.[2][3] Baric's work has drawn criticism from some scientists and members of the public related to chimeric virus experiments conducted at UNC-Chapel Hill.[4]

Career

[edit]

Baric has published multiple articles and book chapters on the epidemiology and genetics of various viruses, including norovirus,[5][6][7] and coronaviruses,[8][9] as well as potential treatments for viral diseases.[10][11]

In 2015, with Shi Zhengli of the Wuhan Institute of Virology, he published an article titled "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence," which describes their work in generating and characterizing a chimeric virus which added the spike of a bat coronavirus (SHC014) onto the backbone of a mouse-adapted SARS-CoV (rMA15).[12] The research related to this article drew criticism from other scientists due to fears that the SHC014-rMA15 chimeric virus could have pandemic potential.[13] This concern was renewed and echoed by members of the public during the COVID-19 pandemic.[14] Experts have noted that the virus was adapted to a mouse model and had decreased virulence in human tissues.[15] The chimeric virus was also less virulent than the wild type rMA15 virus, as is expected in most chimeras.[15]

In 2020, Baric contributed to establishing the official nomenclature and taxonomic classification of SARS-CoV-2.[16] In 2021, he was elected member of the U. S. National Academy of Sciences.[17]

Selected publications

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Ralph S. Baric

View on Grokipedia
from Grokipedia
Ralph S. Baric is an American virologist and the William R. Kenan, Jr. Distinguished Professor of Epidemiology and Professor of Microbiology and Immunology at the University of North Carolina at Chapel Hill, where he has led research on coronaviruses for over three decades. His laboratory employs coronaviruses as models to investigate RNA virus genetics, replication mechanisms, pathogenesis, and cross-species transmission dynamics. Baric's contributions include developing reverse genetic systems for SARS-CoV, enabling targeted studies of viral functions, and characterizing bat-derived coronaviruses with potential for human spillover, which informed early warnings about zoonotic threats and supported the creation of pan-coronavirus vaccine platforms and antivirals. He received the O. Max Gardner Award in 2021 for advancing critical to countermeasures and was elected to the that year for his impact on . Baric's experiments, such as constructing chimeric viruses to evaluate spike protein-mediated —like the study demonstrating a SARS-like coronavirus's capacity to use ACE2 receptors without prior —have highlighted risks of natural emergence but fueled debates over gain-of-function research's , including concerns about lab-acquired infections or accidental releases amid collaborations with institutions like the . These efforts underscore tensions between preempting pandemics through predictive virology and mitigating dual-use risks in high-containment settings.

Early Life and Education

Childhood and Family Background

Ralph S. Baric was born in 1954 in , and grew up in . Public records provide scant details on his immediate family or parental occupations, with no verified accounts of direct familial influences on his later scientific pursuits. The industrial landscape of the mid-20th-century Delaware Valley, encompassing chemical manufacturing hubs like those associated with in nearby Wilmington, represented a regional environment rich in and applications, though no evidence links Baric's household specifically to such sectors. Anecdotal reports describe Baric engaging in outdoor exploration during childhood, potentially sparking an initial curiosity toward biological systems, but formal documentation of early hobbies or school-related scientific activities prior to remains absent from available sources.

Undergraduate and Graduate Studies

Baric earned a degree in Zoology from in , in 1977. He attended the university on a scholarship while pursuing studies in biological sciences, laying a foundation in organismal biology and relevant to later microbial research. He remained at for graduate training, completing a Ph.D. in in 1982. During his doctoral program, Baric worked in the laboratory of Robert E. Johnston, focusing on aspects of microbial that introduced him to RNA virus replication and genetic mechanisms, key precursors to his expertise in viral genetics. Following his Ph.D., Baric undertook a postdoctoral fellowship in at the , completing it in 1986, where he began targeted investigations into coronavirus and host interactions. This advanced training solidified his shift toward , emphasizing approaches for viruses that would underpin his subsequent research trajectory.

Academic and Professional Career

Appointment at University of North Carolina

Ralph Baric joined the at Chapel Hill (UNC) in March 1986 as an in the Department of Parasitology and Laboratory Practice, marking the beginning of his academic career at the institution. He held this position until June 1990, during which time he began developing expertise in , leveraging UNC's resources to initiate research on RNA viruses. In July 1990, Baric transitioned to in the Department of , a role he maintained until June 1993. He was promoted to in both the Department of and the Department of Microbiology and Immunology in July 1993, serving in these positions until 2001. This dual appointment reflected his interdisciplinary focus on and . Baric advanced to full Professor in the Departments of Epidemiology and Microbiology and Immunology in July 2001, a tenure he has held continuously. In 2019, he was appointed the Distinguished Professor in , recognizing his sustained contributions to research at UNC. Concurrent with his initial faculty roles, Baric established a laboratory at UNC utilizing coronaviruses as model systems to investigate genetics and replication mechanisms.

Leadership Roles and Institutional Affiliations

Ralph S. Baric serves as the Distinguished Professor in the Department of at the at Chapel Hill's Gillings School of Global , alongside his professorship in the Department of Microbiology and Immunology. Within UNC, he maintains memberships in key interdisciplinary centers, including the Lineberger Comprehensive Cancer Center, which supports collaborative research on viral and related pathogenesis. He is also affiliated with the Institute for Global Health and Infectious Diseases, facilitating institutional networks focused on emerging pathogen responses. Baric's influence extends to national scientific bodies through his election to the in April 2021, recognizing his contributions to and . In May 2022, he was inducted into the American Academy of Arts and Sciences, further embedding him in elite advisory circles for policy and research prioritization. He has also been elected to the American Academy of , affirming his role in shaping microbiological standards and consortia. In collaborative initiatives, Baric co-founded the Rapidly Emerging Antiviral Drug Development Initiative (READDI) in 2020, partnering with academic and industry entities to accelerate therapeutic platforms against viral threats. He holds advisory positions, such as membership on the Scientific and Clinical Advisory Board of Vaxart, Inc., established in August 2021 to guide oral vaccine strategies. These roles underscore his integration into broader virology networks without encompassing direct research oversight.

Scientific Research and Contributions

Studies on Coronavirus Genetics and Pathogenesis

Baric pioneered the development of reverse genetic systems for , enabling precise manipulation of viral genomes to elucidate replication mechanisms and pathogenic determinants. In the early , his team assembled full-length infectious cDNA clones of severe acute respiratory syndrome (SARS-CoV), facilitating the rescue of molecularly cloned viruses for targeted genetic studies. These platforms, which partition the coronavirus genome into 5–7 overlapping fragments for efficient assembly, allowed systematic dissection of non-structural proteins and functions critical to fidelity and error-prone synthesis. Utilizing chimeric virus models, Baric's research clarified the role of the spike (S) glycoprotein in host cell receptor binding and entry, particularly interactions with (ACE2). For instance, by engineering SARS-CoV backbones with bat-derived S proteins, such as SHC014, studies demonstrated how sequence variations in the receptor-binding domain modulate and efficiency of ACE2 engagement, informing in human airway epithelia. These experiments revealed that adaptive mutations in S can enhance zoonotic potential without altering core replication kinetics, emphasizing receptor compatibility as a key barrier to spillover. Baric's investigations into bat coronavirus reservoirs highlighted empirical risks of zoonotic through genetic analysis of field isolates. Publications from the mid-2000s onward identified diverse SARS-like betacoronaviruses in , with phylogenetic reconstructions showing recombination hotspots that facilitate host-switching. His work quantified RNA recombination frequencies in model systems like mouse (MHV), approaching rates seen in segmented viruses, and linked these events to evolutionary diversification and phenotypes. To probe , Baric employed transcription regulatory network rewiring in SARS-CoV, generating recombinant viruses with altered subgenomic synthesis that reduced progeny fitness and recombination propensity. This approach isolated causal links between genetic circuitry and viral , demonstrating how disruptions in leader-body junctions impair discontinuous transcription while preserving essential replication, thus providing mechanistic insights into modulation independent of host factors.

Antiviral Drug and Vaccine Development

Baric's laboratory at the at Chapel Hill played a pivotal role in the preclinical evaluation of (GS-5734), a analog initially identified as a broad-spectrum antiviral against filoviruses and later adapted for coronaviruses. In 2016–2017 studies, Baric's team demonstrated remdesivir's efficacy in inhibiting replication of SARS-CoV and MERS-CoV in human airway epithelial cultures and mouse models, achieving up to 1000-fold reductions in viral titers at low micromolar concentrations. These findings informed ' advancement of the drug, which received FDA on May 1, 2020, for hospitalized patients, based on clinical trials showing reduced recovery time from 15 to 11 days. Baric described the results as a "game changer" for treatment upon the April 2020 NIAID trial announcement. Building on this, Baric co-founded the Rapidly Emerging Antiviral Drug Development Initiative (READDI) in 2020, a public-private aimed at accelerating broad-spectrum antivirals for viruses, including coronaviruses. READDI has screened thousands of compounds, prioritizing orally bioavailable options like (initially EIDD-2801), which Baric's group tested for efficacy against in airway models, showing viral load reductions comparable to . By 2021, advanced to FDA emergency use for mild-to-moderate in high-risk patients, with phase 3 trials confirming 30% risk reduction in hospitalization or death. READDI's efforts extended to pan-coronavirus candidates, targeting conserved viral enzymes to preempt emerging threats. In vaccine development, Baric collaborated on mRNA platforms leveraging prototype coronaviruses for cross-protection. A 2021 study from his team encoded stabilized spike antigens from and bat sarbecoviruses into lipid nanoparticle-delivered mRNA, eliciting neutralizing antibodies in mice and nonhuman primates that neutralized diverse sarbecoviruses, including and bat-CoV , with titers 5–10-fold higher than monovalent s. This approach informed chimeric spike mRNA , which in 2021 trials protected against sarbecovirus challenge by reducing lung viral loads by over 100-fold. More recently, Baric's work has advanced pan-coronavirus immunogens, including computationally designed mRNA-launched protein vaccines displaying receptor-binding domain () multimers. A 2024 preprint reported these eliciting 5–28-fold higher neutralizing antibody levels against variants and distant betacoronaviruses compared to standard mRNA vaccines in mice. Funded by NIAID grants through 2025, these efforts target S2 subunit-stabilized antigens for broad sarbecovirus immunity, with animal models showing protection against challenge. Amid funding uncertainties for high-containment labs post-COVID, Baric's group continues molecular antiviral pursuits to sustain platform readiness.

Gain-of-Function Research on Emerging Viruses

Ralph S. Baric's laboratory pioneered the development of mouse-adapted severe acute respiratory syndrome coronavirus (SARS-CoV) strains prior to to facilitate studies in a small animal model. By serially passaging the Urbani strain of SARS-CoV through mice, researchers generated variants such as MA15, which exhibited enhanced , causing lethal non-pulmonary infection and high mortality rates in young mice. These adaptations involved in the and other genomic regions that improved replication efficiency and tissue in murine hosts, enabling empirical assessment of viral factors contributing to severe disease outcomes. A landmark experiment in occurred in 2015, when Baric collaborated with Shi Zhengli's team at the to evaluate the emergence potential of bat-derived SARS-like coronaviruses. The study constructed a chimeric , designated rSHC014-SARS-MA15, by replacing the spike glycoprotein of the mouse-adapted SARS-CoV MA15 backbone with that from SHC014-CoV, a SARS-like isolated from Chinese horseshoe bats. This recombinant demonstrated efficient replication in primary airway epithelial cells, utilization of human ACE2 receptors without prior adaptation, resistance to therapies targeting SARS-CoV, and induction of significant and immunopathology in aged mice. The technical approach utilized systems to synthesize full-length cDNAs, confirming the spike protein's role in conferring infectivity potential. These experiments provided data on viral adaptation thresholds, revealing that certain bat spikes possess intrinsic capacity for human cell entry and , potentially bypassing intermediate hosts in spillover events. Baric's rationale emphasized predictive modeling of zoonotic risks from diverse sarbecovirus reservoirs, arguing that such chimeras yield quantifiable metrics on transmissibility enhancements and inform proactive and antiviral design against pre-emergent threats. Following the 2014-2017 U.S. moratorium on certain gain-of-function studies, Baric's proposals navigated the Potential Pandemic Pathogen Care and Oversight (P3CO) framework to resume work on engineered coronaviruses, focusing on empirical thresholds for and host range expansion in emerging viral lineages.

Controversies and Public Debates

Debates Over Gain-of-Function Research Risks

Gain-of-function (GoF) research, which involves enhancing the transmissibility or virulence of pathogens to study potential pandemic threats, has sparked intense debate, particularly regarding experiments conducted by Ralph Baric at the University of North Carolina. Proponents, including Baric, contend that such studies are crucial for anticipating natural spillover events from animal reservoirs, as demonstrated in his 2015 reconstruction of a bat-derived SARS-like coronavirus (SHC014-CoV) that exhibited limited but notable adaptation to human airway cells, underscoring the need to model evolutionary pathways for proactive vaccine and therapeutic development. This approach, they argue, mirrors real-world viral adaptations observed in nature, enabling identification of high-risk precursors before outbreaks occur. Critics of GoF research emphasize of accidents, asserting that failures in even high-containment facilities (BSL-3 and BSL-4) elevate the of unintended releases that could initiate pandemics. Historical incidents include the 1977 reemergence of H1N1 influenza, widely attributed to a laboratory escape during development in either or the , which caused millions of infections primarily among young adults due to pre-1968 immunity gaps. Similarly, the 1979 Sverdlovsk anthrax outbreak in the , originating from a facility, resulted in at least 66 deaths from aerosolized spores, highlighting systemic vulnerabilities in pathogen handling despite official denials at the time. These cases illustrate non-zero probabilities of containment breaches, with analyses estimating lab-acquired infections occurring at rates of up to 2.8 per 1,000 researchers in settings, compounded by underreporting. The 2014 U.S. federal moratorium on certain GoF funding, announced on October 17 by the White House Office of Science and Technology Policy, was precipitated by a series of safety lapses, including inadvertent exposures at the CDC affecting 75-82 personnel and mishandling of H5N1 and H5N8 samples, prompting a reevaluation of risks for , , and studies. Although not directly tied to Baric's lab, the pause interrupted ongoing projects, including aspects of his work, fueling arguments that regulatory gaps allow continuation of high-risk experiments under narrower definitions. Baric has responded to criticisms by asserting that his chimeric coronavirus constructs, such as the SHC014-MA15 hybrid, did not meet the NIH's specific GoF criteria under the moratorium, which targeted enhancements reasonably anticipated to increase transmissibility or pathogenicity in mammals, as his strains showed no significant airborne spread in models. He maintains adherence to institutional protocols at UNC's BSL-3 facility, emphasizing layered safeguards like negative-pressure rooms and to mitigate escape risks. However, dissenting experts question the efficacy of self-reported oversight, citing definitional ambiguities that permitted resumption of similar work post-2017 under the HHS P3CO framework, which some view as insufficiently stringent given historical precedents.

Role in COVID-19 Origins Investigations

In early 2020, Ralph Baric contributed to initial analyses of the genome sequence, noting the presence of a cleavage site (FCS) at the S1/S2 junction of the , a feature absent in closely related sarbecoviruses. Private emails among virologists, including Kristian Andersen, highlighted concerns about this FCS and other genomic elements appearing potentially engineered, with Andersen writing to on January 31, 2020, that "some of the features...look engineered." Baric provided comments on drafts of related origin commentaries, influencing revisions amid scrutiny of manipulation risks, though these discussions preceded public publications favoring emergence. Baric's laboratory techniques, including and serial passaging of chimeric coronaviruses, informed broader contexts relevant to origin debates. He maintained indirect ties to 's 2018 DEFUSE proposal, which proposed inserting human-specific FCS motifs into SARS-related coronaviruses to study infectivity enhancements; Baric's UNC lab was slated for a subcontract to engineer chimeric spike proteins for inoculation experiments. The unfunded project drew criticism from lab-leak proponents, who argued that such manipulations or undirected serial passages in could replicate SARS-CoV-2's FCS and receptor-binding adaptations without deliberate design. During 2023–2024 congressional inquiries, Baric testified that a lab-related incident remained plausible, assigning it a probability of at least 15–20% or higher given biosafety lapses at institutes, but he prioritized zoonotic spillover at the Huanan Seafood Market based on genetic and spatiotemporal clustering of early cases. He contrasted this with lab-leak scenarios lacking direct evidence, such as infected researchers or matching viral strains in lab records, while acknowledging the FCS's evolutionary novelty as unresolved. In January 2026, the North Carolina Court of Appeals upheld a lower court's decision denying U.S. Right to Know access to approximately 50,000 pages of records from the University of North Carolina related to Baric's coronavirus research collaborations with the Wuhan Institute of Virology, supporting the university's invocation of the research exemption under the North Carolina Public Records Act.

Criticisms of Research Safety and Oversight

In October 2014, the U.S. government imposed a funding pause on gain-of-function (GoF) research involving , , and viruses, prompted by safety incidents at the CDC and USAMRIID, including mishandling of and H5N1. This moratorium directly halted ongoing experiments in Ralph Baric's (UNC) laboratory, where NIH had funded chimeric construction to assess pandemic potential; Baric confirmed compliance, stating the NIH instructed cessation of such work pending risk reassessment. Critics, including congressional investigators, later argued that the pause exposed systemic underestimation of hazards in federally supported , as UNC's BSL-3 facilities continued handling engineered pathogens with protocols deemed insufficient for enhanced transmissibility risks. Post-pause, UNC's high-containment lab under Baric reported multiple near-misses involving potential exposures to lab-engineered coronaviruses. In February 2016, a researcher was bitten by a mouse infected with a chimeric SARS-associated coronavirus, penetrating gloves; the individual was not quarantined but monitored symptoms twice daily for 10 days without developing illness. Between 2015 and 2020, four incidents led to medical monitoring for six personnel exposed to modified SARS coronaviruses, and two others to a lab-created MERS variant; affected staff reported symptoms twice daily while maintaining public activities, raising questions about quarantine rigor for potential aerosol or contact transmission in GoF contexts. An April 2021 event involved a mouse bite with genetically altered SARS-CoV-2, prompting 14-day self-quarantine and local health notification, but no broader facility lockdown. These incidents, documented in federal reports, underscored persistent vulnerabilities in handling predictability-challenged pathogens, despite BSL-3 enhancements, with detractors citing them as evidence of inadequate hazard scaling to experimental virulence. Following the COVID-19 emergence, Baric's lab faced funding disruptions tied to heightened oversight scrutiny. NIH terminated select UNC grants in 2020 amid Trump administration cuts to pandemic-related allocations, though some were later restored; by 2025, broader NIH directives eliminated ongoing COVID grants, jeopardizing a $65 million award Baric's team secured in 2022 for coronavirus countermeasures. Proposed caps on indirect costs at 15%—down from UNC's 55% rate—threatened operational sustainability, including biosafety infrastructure, while HHS nominee Robert F. Kennedy Jr. advocated pausing infectious disease funding for eight years to redirect toward chronic conditions, explicitly critiquing GoF precedents. These measures, advanced by Republican-led bills like S. 4667 and H.R. 1048 banning genetic engineering of potential pandemic pathogens or ties to entities in China, stemmed from audits revealing NIH's inconsistent enforcement of reporting and risk mitigation in high-containment grants. Right-leaning analyses, including House findings, have highlighted conflicts in NIH grant administration, where funding incentives for novel prediction outpaced safeguards, enabling labs like UNC's to pursue experiments with limited real-time auditing. Such critiques posit that dependency on renewable NIH awards fostered incremental normalization, as evidenced by UNC's exposure logs showing no systemic protocol overhauls post-2016 despite repeated breaches, potentially amplifying escape probabilities in under-monitored settings. Congressional probes, including Baric's 2023 deposition, emphasized these lapses as symptomatic of federal underinvestment in containment redundancy relative to GoF ambitions.

Recognition and Legacy

Awards and Honors

Baric was appointed the William R. Kenan, Jr. Distinguished Professor of Epidemiology at the University of North Carolina at Chapel Hill, an endowed position recognizing sustained research excellence and publication impact in virology. In 2019, he was named a UNC Distinguished Professor, one of the university's highest faculty honors for contributions to scholarship and teaching. In 2021, Baric was elected to the , acknowledging his foundational work on genetics, replication, and cross-species transmission mechanisms. The following year, 2022, he was elected to the American Academy of Arts and Sciences, further honoring his advancements in understanding . Baric has been designated a Highly Cited Researcher in the top 1% by Clarivate Analytics for multiple years, including 2021 through 2024, based on exceptional citation impact of his publications in and .

Impact on Virology and Pandemic Preparedness

Baric's development of reverse genetic systems for coronaviruses in the early facilitated the rapid generation of infectious clones and chimeric viruses, enabling precise genetic manipulation to study and prototype . These platforms were instrumental during the outbreak in 2003, where full-length cDNA clones allowed phenotypic comparisons between wild-type and engineered viruses, accelerating antiviral screening and candidates. Similarly, for MERS-CoV identified in , Baric's cassette-based infectious clone supported strategies and live-attenuated designs, demonstrating in animal models and informing protocols. Empirical validation came from these systems' role in predicting zoonotic spillover risks, as chimeric constructs encoding bat-derived spikes highlighted potential for human adaptation without requiring natural isolates. This work shaped dual-use research policies by providing models of viral emergence that underscored both preparedness benefits and biosafety hazards, yet faced criticism for inadequately accounting for accident incentives in international partnerships lacking stringent oversight. Baric's collaborations, including with researchers, generated chimeras that enhanced transmissibility in human cells, informing U.S. frameworks like the 2017 HHS P3CO for enhanced potential pandemic pathogens. However, documented lab incidents at UNC, such as exposures and failures between 2015 and 2019, exemplified causal risks from handling engineered pathogens, amplifying calls to restrict gain-of-function enhancements amid evidence of underreported vulnerabilities in global networks. Institutional tendencies in academia to prioritize over have, in this , contributed to policy debates favoring empirical risk assessments over unchecked expansion. As of 2025, Baric's platforms retain utility for proactive antiviral stockpiling, as seen in the READDI consortium's rapid deployment of broad-spectrum inhibitors against emerging threats, yet their replication demands stringent GoF moratoriums to emphasize and over functional enhancements. Recent U.S. executive actions restricting overseas funding for high-risk experiments reflect this balance, prioritizing empirical advances in backbones while mitigating leak potentials evidenced by historical near-misses and the aftermath. Cautious adoption—focusing on directed attenuation rather than transmissibility gains—aligns with causal realism in pandemic preparedness, ensuring tools like Baric's inform defenses without amplifying existential threats.

References

  1. https://sph.unc.edu/adv_profile/ralph-s-baric-phd/
  2. https://globalhealth.unc.edu/people/ralph-s-baric-phd/
  3. https://unclineberger.org/directory/ralph-s-baric/
  4. https://www.nasonline.org/directory-entry/ralph-s-baric-lhxzsj/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4797993/
  6. https://sph.unc.edu/sph-news/dr-ralph-baric-receives-o-max-gardner-award-for-coronavirus-research/
  7. https://unclineberger.org/news/baric-inducted-into-national-academy-of-sciences/
  8. https://oversight.house.gov/wp-content/uploads/2024/04/Baric-TI-Transcript.pdf
  9. https://www.newsobserver.com/news/local/education/article242992686.html
  10. https://nap.nationalacademies.org/read/12970/chapter/9
  11. https://sph.unc.edu/wp-content/uploads/sites/112/2016/01/Baric-Ralph-S.pdf
  12. https://cals.ncsu.edu/plant-and-microbial-biology/news/2020-plant-and-microbial-biology-departmental-awards-and-recognitions/
  13. https://www.newsobserver.com/news/politics-government/article307772560.html
  14. https://sph.unc.edu/wp-content/uploads/sites/112/2020/04/Baric-SPHCV-Website-04-2020.pdf
  15. https://sph.unc.edu/sph-news/baric-named-a-2019-unc-distinguished-professor/
  16. https://sph.unc.edu/sph-news/baric-among-unc-chapel-hill-faculty-named-to-national-academy-of-sciences/
  17. https://www.amacad.org/person/ralph-s-baric
  18. https://news.unchealthcare.org/2022/05/ting-baric-elected-to-american-academy-of-arts-sciences/
  19. https://unclineberger.org/news-archives/baric/
  20. https://readdi.org/team/ralph-s-baric/
  21. https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-creation-new-scientific-and-clinical-advisory
  22. https://pubmed.ncbi.nlm.nih.gov/14569023/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC7120940/
  24. https://www.nature.com/articles/nm.3985
  25. https://www.pnas.org/doi/10.1073/pnas.1517719113
  26. https://grantome.com/grant/NIH/R01-AI023946-06
  27. https://www.pnas.org/doi/10.1073/pnas.0605438103
  28. https://pubmed.ncbi.nlm.nih.gov/16891412/
  29. https://sph.unc.edu/sph-news/remdesivir-developed-at-unc-chapel-hill-proves-effective-against-covid-19-in-niaid-human-clinical-trials/
  30. https://uncnews.unc.edu/2020/04/29/positive-remdesivir-clinical-trial-results-from-carolina-innovation/
  31. https://news.unchealthcare.org/2021/10/carolina-research-leads-to-effective-experimental-pill-to-treat-covid-19/
  32. https://www.northcarolina.edu/news/ralph-baric-receives-o-max-gardner-award-for-coronavirus-research/
  33. https://www.nih.gov/news-events/nih-research-matters/experimental-vaccine-protects-against-multiple-coronaviruses
  34. https://www.nature.com/articles/s41586-021-03594-0
  35. https://www.science.org/doi/10.1126/science.abi4506
  36. https://reporter.nih.gov/search/2ieqzHAWVUCBoLqM52CA7g/project-details/10420511
  37. https://www.biorxiv.org/content/10.1101/2024.07.22.604655v1
  38. https://www.nature.com/articles/s41467-024-45404-x
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC2787736/
  40. https://www.technologyreview.com/2021/07/26/1030043/gain-of-function-research-coronavirus-ralph-baric-vaccines/
  41. https://www.nature.com/articles/nature.2015.18787
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4542197/
  43. https://www.nytimes.com/2021/06/20/world/europe/coronavirus-lab-anthrax.html
  44. https://www.sciencedirect.com/science/article/pii/S0755498225000107
  45. https://www.science.org/content/article/us-halts-funding-new-risky-virus-studies-calls-voluntary-moratorium
  46. https://www.science.org/content/article/nih-lifts-3-year-ban-funding-risky-virus-studies
  47. https://www.npr.org/sections/health-shots/2014/11/07/361219361/how-a-tilt-toward-safety-stopped-a-scientists-virus-research
  48. https://www.theassemblync.com/education/higher-education/unc-chapel-hill-lab-baric-five-years-covid-19/
  49. https://www.ncbi.nlm.nih.gov/books/NBK285583/
  50. https://republicans-energycommerce.house.gov/posts/ec-republican-leaders-reveal-nih-mismanaged-concerns-surrounding-ecohealth-alliances-risky-research-in-china
  51. https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00701
  52. https://usrtk.org/covid-19-origins/scientists-who-authored-article-denying-lab-engineering-of-sars-cov-2-privately-acknowledged-possible-lab-origin-emails-show/
  53. https://www.congress.gov/117/meeting/house/114658/documents/HHRG-117-IF14-20220427-SD003.pdf
  54. https://theintercept.com/2021/09/23/coronavirus-research-grant-darpa/
  55. https://www.documentcloud.org/documents/21066966-defuse-proposal
  56. https://www.vanityfair.com/news/story/ralph-baric-wuhan-lab-leak
  57. https://www.carolinajournal.com/judges-reject-public-records-case-linked-to-unc-and-covid-19s-origins/
  58. https://osp.od.nih.gov/wp-content/uploads/2022/11/Gain_of_Function_Deliberative_Process_Written_Public_Comments.pdf
  59. https://oversight.house.gov/wp-content/uploads/2024/12/12.04.2024-SSCP-FINAL-REPORT.pdf
  60. https://www.propublica.org/article/near-misses-at-unc-chapel-hills-high-security-lab-illustrate-risk-of-accidents-with-coronaviruses
  61. https://www.gao.gov/assets/680/671678.pdf
  62. https://www.newsobserver.com/news/politics-government/article307770080.html
  63. https://www.congress.gov/bill/118th-congress/senate-bill/4667/text
  64. https://oversight.house.gov/release/hearing-wrap-up-nih-repeatedly-refutes-ecohealth-alliance-president-dr-peter-daszaks-testimony-tabak-testimony-reveals-federal-grant-procedures-in-need-of-serious-reform/
  65. https://unclineberger.org/news/baric-ting-elected-to-american-academy-of-arts-sciences/
  66. https://www.pnas.org/doi/10.1073/pnas.1311542110
  67. https://grantome.com/grant/NIH/R01-AI059136-04
  68. https://journals.asm.org/doi/10.1128/mbio.00103-21
  69. https://www.technologyreview.com/2021/06/29/1027290/gain-of-function-risky-bat-virus-engineering-links-america-to-wuhan/
  70. https://www.nytimes.com/2025/03/03/opinion/risky-virus-research.html
  71. https://www.unc.edu/discover/readdi-not-reactive/
  72. https://www.wsws.org/en/articles/2025/05/13/txny-m13.html
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC9458934/
Add your contribution
Related Hubs
User Avatar
No comments yet.